Pharmacovigilance

British Journal of Clinical Pharmacology

Volumn 73, Issue 6, 2012, Pages 979-982

  Edwards, I Ralph ^a  

^a UPPSALA MONITORING CENTRE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL EFFECTIVENESS; DRUG SURVEILLANCE PROGRAM; HUMAN; INTERPERSONAL COMMUNICATION; KNOWLEDGE MANAGEMENT; MEDICAL DECISION MAKING; NOTE; PHARMACOEPIDEMIOLOGY; PRIORITY JOURNAL; TECHNOLOGY;

ADVERSE DRUG REACTION REPORTING SYSTEMS; COMMUNICATION; DATA MINING; DATABASES, FACTUAL; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOVIGILANCE; PUBLIC HEALTH;

EID: 84860653563     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2012.04249.x     Document Type: Note

References (17)

1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279: 1200-5.
2. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, Farrar K, Park BK, Breckenridge AM. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18820 patients. BMJ 2004; 329: 15-9.
3. Finney DJ. The design and logic of a monitor of drug use. J Chronic Dis 1965; 18: 77-98.
4. International Conference on Harmonization. Clinical Safety Data Management: Data Elements for Transmission of Individual Case Safety Reports (ICH E2B(R2)). Geneva: International Conferences on Harmonization, 5 February 2001. Available at (last accessed 3 January 2012).
5. Edwards IR, Lindquist M, Wiholm BE, Napke E. Quality criteria for early signals of possible adverse drug reactions. Lancet 1990; 336: 156-8.
6. Waller PC, Evans SJ. A model for the future conduct of pharmacovigilance. Pharmacoepidemiol Drug Saf 2003; 12: 17-29.
7. Aronson JK, Ferner RE. Joining the DoTS: new approach to classifying adverse drug reactions. BMJ 2003; 327: 1222-5.
8. Aronson JK, Price D, Ferner RE. A strategy for regulatory action when new adverse effects of a licensed product emerge. Drug Saf 2009; 32: 91-8.
9. Ferner RE, Aronson JK. EIDOS: a mechanistic classification of adverse drug effects. Drug Saf 2010; 33: 15-23.
10. Tang A. Evaluating the evidence base in pharmacovigilance decision making. PhD Thesis, University of Portsmouth. Available at (last accessed 3 January 2012).
11. Hill AB. The environment and disease: association or causation? Proc R Soc Med 1965; 58: 295-300.
12. Howick J, Glasziou P, Aronson JK. The evolution of evidence hierarchies: what can Bradford Hill's 'guidelines for causation' contribute? J R Soc Med 2009; 102: 186-94.
13. Green J, Czanner G, Reeves G, Watson J, Wise L, Beral V. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: nested case-control study. BMJ 2010; 341: c4444.
14. Cardwell CR, Abnet CC, Cantwell MM, Murray LJ. Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA 2010; 304: 657-63.
15. Wysowski DK. Oral bisphosphonates and oesophageal cancer. BMJ 2010; 341: c4506.
16. Health talk on-line. Available at (last accessed 3 January 2012).
17. Intellectual masturbation. Available at (last accessed 3 January 2012).